I have pasted below material taken from Clusterstock and would add to the list 3M, who makes the masks that will likley be used if this thing reaches pandemic proportions.
----------------------...
The swine flu outbreak has come during a horribly vulnerable time for the global economy, but at least on Monday, toxic balance sheets won't be the #1 news story.
Instead we'll be trying to figure out if this is the big one, or if it's just a prelude.
Two of the ones to watch tomorrow: Biocryst (BCRX) and Novavax (NVAX), vaccine makers which were up 26% and 75% respectively on Friday as news emerged of the disease striking in Mexico. We'll be shocked if they don't go crazy again on Monday, now that the story's gotten much bigger and because Novavax still has a market cap of under $100 million. It won't take much to make it go crazy.
Other companies that may profit from swine flu include Roche -- who's Tamiflu has had some effect and Gilead (GILD), which gets royalties from its sale.
This blog offers up some more speculative names including NanoViricides (NNVC) and Sinovac Biotech (SVA)
A stock we'd expect to see selling in: Hormel (HRL).
Any other ideas and guesses as to how the story will effect the markets and individual stocks? We'd love to hear 'em.
I have reviewed my own indicators and read many blogs and believe there are legitimate reasons to offer divergent opinions as to market direction over the next several weeks.
Most technical signals are mixed with a bias towards selling, though the MACD for the SPX suggests the rally will continue. Coversely,RSI, Williams, and Ultimate Oscillator for the SPX tend to suggest a sell-off though the signals are not at compelling levels. A proprietary price/volume indicator suggets a fall in the SP500.
In the recent rally, a significant downward trendline was breached but it failed to hold putting in place a possible pivot point. It's fair to say we are at the 50 yard line and for the bulls to have there way we will need to see the SPX move through 786 and then tackle the more difficult resistance line of 805-808.
Since most of the recent rally stemmed from gains in financials and materials, resolution may turn on how much more short covering and taking of profits will influence index direction. Announcements from Washington will continue to play a role and could prove to be decisive.
Possible Swine Flu Profit Trades [View article]
----------------------...
The swine flu outbreak has come during a horribly vulnerable time for the global economy, but at least on Monday, toxic balance sheets won't be the #1 news story.
Instead we'll be trying to figure out if this is the big one, or if it's just a prelude.
Two of the ones to watch tomorrow: Biocryst (BCRX) and Novavax (NVAX), vaccine makers which were up 26% and 75% respectively on Friday as news emerged of the disease striking in Mexico. We'll be shocked if they don't go crazy again on Monday, now that the story's gotten much bigger and because Novavax still has a market cap of under $100 million. It won't take much to make it go crazy.
Other companies that may profit from swine flu include Roche -- who's Tamiflu has had some effect and Gilead (GILD), which gets royalties from its sale.
This blog offers up some more speculative names including NanoViricides (NNVC) and Sinovac Biotech (SVA)
A stock we'd expect to see selling in: Hormel (HRL).
Any other ideas and guesses as to how the story will effect the markets and individual stocks? We'd love to hear 'em.
Bear Market Rally Not Over Yet [View article]
Most technical signals are mixed with a bias towards selling, though the MACD for the SPX suggests the rally will continue. Coversely,RSI, Williams, and Ultimate Oscillator for the SPX tend to suggest a sell-off though the signals are not at compelling levels. A proprietary price/volume indicator suggets a fall in the SP500.
In the recent rally, a significant downward trendline was breached but it failed to hold putting in place a possible pivot point. It's fair to say we are at the 50 yard line and for the bulls to have there way we will need to see the SPX move through 786 and then tackle the more difficult resistance line of 805-808.
Since most of the recent rally stemmed from gains in financials and materials, resolution may turn on how much more short covering and taking of profits will influence index direction. Announcements from Washington will continue to play a role and could prove to be decisive.